BioPharma Resources

Investigational drug · Phase 3

LBL-024

Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

11

11 still active

All registered trials

11

Any phase or sponsor naming "LBL-024"

First trial start

2022

Jan 6, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "LBL-024", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Advanced Solid Tumour
  • Advanced Extrapulmonary Neuroendocrine Carcinoma
  • Metastatic Colorectal Carcinoma
  • Ovarian Cancer
  • Advanced Solid Tumor
  • Triple Negative Breast Cancer
  • Advanced Melanoma
  • Advanced Neuroendocrine Carcinoma

Approved drugs for the same conditions: Breast cancer · Melanoma · Ovarian cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "LBL-024" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.